Current guidelines and prospects for using novel oral anticoagulants for nonvalvular atrial fibrillation
The capabilities of antithrombotic therapy to prevent systemic thromboembolic events in nonvalvular atrial fibrillation (AF) are substantially extended after clinically introducing novel oral anticoagulants (NOACs), such as dabigatran, rivaroxaban, and apixaban. World clinical experience with NOACs...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Russo |
| Publicado em: |
IMA-PRESS LLC
2014-12-01
|
| Colecção: | Неврология, нейропсихиатрия, психосоматика |
| Assuntos: | |
| Acesso em linha: | https://nnp.ima-press.net/nnp/article/view/448 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|